Browse > Article
http://dx.doi.org/10.7314/APJCP.2013.14.2.877

Gemcitabine Alone or in Combination with Cisplatin for Advanced Biliary Tract Carcinomas: an Overview of Clinical Evidence  

Sun, Tian-Tian (Shanghai Institute of Digestive Disease, Shanghai Jiaotong University School of Medicine Renji Hospital)
Wang, Ji-Lin (Shanghai Institute of Digestive Disease, Shanghai Jiaotong University School of Medicine Renji Hospital)
Fang, Jing-Yuan (Shanghai Institute of Digestive Disease, Shanghai Jiaotong University School of Medicine Renji Hospital)
Publication Information
Asian Pacific Journal of Cancer Prevention / v.14, no.2, 2013 , pp. 877-883 More about this Journal
Abstract
Background and Objective: There has been no universally agreed standard chemotherapy regimen for patients with advanced biliary tract carcinomas (BTC). We aimed to fully display and evaluate the clinical evidence for gemcitabine or gemcitabine-cisplatin combination for advanced BTC. Methods: Systematic searches were performed to identify relevant randomized controlled trials (RCTs) and uncontrolled trials. Overall survival (OS), progression-free survival (PFS), overall response rates (ORR), tumor control rates (TCR), and toxicity were evaluated. Evidence levels of the results were evaluated with the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach. Results: Results of the eleven gemcitabine-cisplatin trials and ten gemcitabine trials showed both chemotherapy regimens had benefits with reference to mean OS (8.63 vs. 8.79 months), mean PFS (4.86 vs. 4.72 months), pooled ORR (25.3% vs. 19.6%) and TCR (55.2% vs. 53.1%). Two RCTs showed the gemcitabine-cisplatin combination to prolong the mean PFS (mean difference [MD] 2.57, 95%CI 1.69 3.45), substantially increasing the mean OS (MD 3.59, 95% CI 3.48 3.71), and producing a similar effect in ORR (risk ratio [RR] 1.59, 95%CI 1.04 2.43), increasing TCR (RR 1.15, 95%CI 1.02 1.31) compared with gemcitabine alone, with generally manageable grade 3 or 4 adverse events. The evidence level of OS was moderate, and other outcomes (ORR, PFS, TCR, anaemia, neutropenia) were at low evidence levels. Conclusion: Available evidence was limited with low quality, which showed that both gemcitabine-cisplatin and gemcitabine alone had clinical activity with acceptable safety profiles, and gemcitabine-cisplatin appeared to be more useful for advanced BTC patients than gemcitabine alone.
Keywords
Biliary tract neoplasms; gemcitabine; cisplatin; combination therapy;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Akl E, Muti P, Schunemann H (2008). Anticoagulation in patients with cancer: an overview of reviews. Pol Arch Med Wewn, 118, 183-93.
2 Albores-Saavedra J, Henson D,Sobin L (1992). The WHO histological classification of tumors of the gallbladder and extrahepatic bile ducts. Cancer, 70, 410-4.   DOI   ScienceOn
3 Andrea C, Francesco C (2003). Squamous-cell and non-squamous-cell carcinomas of the gallbladder have different risk factors. Lancet Oncol, 4, 393.
4 Bergman A, Ruiz van Haperen V, Veerman G, et al (1996). Synergistic interaction between cisplatin and gemcitabine in vitro. Clin Cancer Res, 2, 521.
5 Charoentum C, Thongprasert S, Chewaskulyong B, et al (2007). Experience with gemcitabine and cisplatin in the therapy of inoperable and metastatic cholanglocarcinoma. World J Gastroenterol, 13, 2852-4.
6 Comella P, Palmieri G, Lorusso V, et al (1996). Double biochemical modulation of 5-fluorouracil by methotrexate and levo-folinic acid in the treatment of advanced digestive tract malignancies. Eur J Cancer, 32, 1719-26.   DOI   ScienceOn
7 Crino L, Scagliotti G, Marangolo M, et al (1997). Cisplatin-gemcitabine combination in advanced non-small-cell lung cancer: a phase II study. J Clin Oncol, 15, 297.
8 Delbaldo C, Laurent A, Grenier J, et al (2009). Management of biliary bract carcinomas. Revue du Praticien, 59, 469-73.
9 De Groen P, Gores G, LaRusso N, et al (1999). Biliary tract cancers. New Engl J Med, 341, 1368.   DOI   ScienceOn
10 Doval D, Sekhon J, Gupta S, et al (2004). A phase II study of gemcitabine and cisplatin in chemotherapy-naive, unresectable gall bladder cancer. Brit J Cancer, 90, 1516-20.   DOI   ScienceOn
11 Ducreux M, Rougier P, Fandi A, et al (1998). Effective treatment of advanced biliary tract carcinoma using 5-fluorouracil continuous infusion with cisplatin. Ann Oncol, 9, 653.   DOI   ScienceOn
12 Eng C, Ramanathan RK, Wong MK, et al (2004). A Phase II trial of fixed dose rate gemcitabine in patients with advanced biliary tree carcinoma. Am J Clin Oncol, 27, 565-9.   DOI   ScienceOn
13 Furuse J, Okusaka T, Bridgewater J, et al (2011). Lessons from the comparison of two randomized clinical trials using gemcitabine and cisplatin for advanced biliary tract cancer. Crit Rev Oncol Hematol, 80, 31-9.   DOI   ScienceOn
14 Gallardo J, Fodor M, Gamargo C, et al (1998). Efficacy of gemcitabine in the treatment of patients with gallbladder carcinoma. Cancer, 83, 2419-20.   DOI
15 Gallardo J, Rubio B, Fodor M, et al (2001). A phase II study of gemcitabine in gallbladder carcinoma. Ann Oncol, 12, 1403.   DOI   ScienceOn
16 Gebbia V, Majello E, Testa A, et al (1996). Treatment of advanced adenocarcinomas of the exocrine pancreas and the gallbladder with 5-fluorouracil, high dose levofolinic acid and oral hydroxyurea on a weekly schedule: Results of a multicenter study of the Southern Italy Oncology Group (GOIM). Cancer, 78, 1300-7.   DOI
17 Giuliani F, Gebbia V, Maiello E, et al (2006). Gemcitabine and cisplatin for inoperable and/or metastatic biliary tree carcinomas: a multicenter phase II study of the Gruppo Oncologico dell'Italia Meridionale (GOIM). Ann Oncol, 17, vii73-7.   DOI   ScienceOn
18 Goldstein D, Gainford M, Brown C, et al (2011). Fixed-dose-rate gemcitabine combined with cisplatin in patients. with inoperable biliary tract carcinomas. Cancer Chemother Pharmacol, 67, 519-25.   DOI   ScienceOn
19 Heinrich S, Sch fer M, Weber A, et al (2008). Neoadjuvant chemotherapy generates a significant tumor response in resectable pancreatic cancer without increasing morbidity: results of a prospective phase II trial. Ann Surg, 248, 1014.   DOI   ScienceOn
20 Hitt R, Castellano D, Hidalgo M, et al (1998). Phase II trial of cisplatin and gemcitabine in advanced squamous-cell carcinoma of the head and neck. Ann Oncol, 9, 1347.   DOI   ScienceOn
21 Higgins JP, Green S (2009). Cochrane Handbook for Systematic Reviews of Interventions 5.0.1 [updated September 2009]. http://www.cochrane-handbook.org/ (accessed 16 June 2010) edition. The Cochrane Collaboration.
22 Kim S, Park J, Lee J, et al (2006). A phase II study of gemcitabine and cisplatin in advanced biliary tract cancer. Cancer, 106, 1339-46.   DOI   ScienceOn
23 Levy AD, Murakata LA, Rohrmann CA Jr (2001). Gallbladder carcinoma: radiologic-pathologic correlation. Radiographics, 21, 295-314.   DOI   ScienceOn
24 Lee G, Kang J, Kim H, et al (2006). Combination chemotherapy with gemcitabine and cisplatin as first-line treatment for immunohistochemically proven cholangiocarcinoma. Am J Clin Oncol, 29, 127.   DOI   ScienceOn
25 Lee J, Kim T, Lee M, et al (2008). Phase II trial of gemcitabine combined with cisplatin in patients with inoperable biliary tract carcinomas. Cancer Chemoth Pharmacol, 61, 47-52.
26 Lin MH, Chen JS, Chen HH, et al (2003). A phase II trial of gemcitabine in the treatment of advanced bile duct and periampullary carcinomas. Chemotherapy, 49, 154-8.   DOI   ScienceOn
27 Meyerhardt J, Zhu A, Stuart K, et al (2008). Phase-II study of gemcitabine and cisplatin in patients with metastatic biliary and gallbladder cancer. Digest Dis Sci, 53, 564-70.   DOI
28 Metzger J, Sauerbruch T, Ko Y, et al (1998). Phase II study with gemcitabine in gallbladder and biliary tract carcinomas. Onkologie, 21, 232-4.   DOI   ScienceOn
29 Okusaka T, Ishii H, Funakoshi A, et al (2006). Phase II study of single-agent gemcitabine in patients with advanced biliary tract cancer. Cancer Chemoth Pharmacol, 57, 647-6.   DOI
30 Okusaka T, Nakachi K, Fukutomi A, et al (2010). Gemcitabine alone or in combination with cisplatin in patients with biliary tract cancer: a comparative multicentre study in Japan. Brit J Cancer, 103, 469-74.   DOI   ScienceOn
31 Pasetto L, D'Andrea M, Falci C, et al (2007). Gemcitabine in advanced biliary tract cancers. Crit Rev Oncol/Hematol, 61, 230-42.   DOI   ScienceOn
32 Patel T (2002). Worldwide trends in mortality from biliary tract malignancies. BMC Cancer, 2, 10.   DOI
33 Patt Y, Hassan M, Lozano R, et al (2001). Phase II trial of cisplatin, interferon alpha-2b, doxorubicin, and 5-fluorouracil for biliary tree cancer. Clin Cancer Res, 7, 3375-80.
34 Park B, Kim Y, Park J, et al (2006). Phase II study of gemcitabine and cisplatin in advanced biliary tract cancer. J Gastroenterol Hepatol, 21, 999-1003.   DOI   ScienceOn
35 Park J, Oh S, Kim S, et al (2005). Single-agent gemcitabine in the treatment of advanced biliary tract cancers: a phase II study. Japn J Clin Oncol, 35, 68.   DOI   ScienceOn
36 Penz C, Kornek G, Raderer M, et al (2001). Phase II trial of two-weekly gemcitabine in patients with advanced biliary tract cancer. Ann Oncol, 12, 183.   DOI   ScienceOn
37 Rau S, Autschbach F, Riedel HD, et al (2008). Expression of the multidrug resistance proteins MRP2 and MRP3 in human cholangiocellular carcinomas. Eur J Clin Invest, 38, 134-42.   DOI   ScienceOn
38 Schunemann H, Jaeschke R, Cook D, et al (2006). An official ATS statement: grading the quality of evidence and strength of recommendations in ATS guidelines and recommendations. Am J Respir Crit Care Med, 174, 605-14   DOI   ScienceOn
39 Sasaki T, Isayama H, Nakai Y, et al (2011). Feasibility study of gemcitabine and cisplatin combination chemotherapy for patients with refractory biliary tract cancer. Investigational New Drugs, 29,1488-93.   DOI   ScienceOn
40 Smith G, Bukowski R, Hewlett J, et al (1984). Hepatic artery infusion of 5-fluorouracil and mitomycin C in cholangiocarcinoma and gallbladder carcinoma. Cancer, 54, 1513-6.   DOI
41 Thongprasert S, Napapan S, Charoentum C, et al (2005). Phase II study of gemcitabine and cisplatin as first-line chemotherapy in inoperable biliary tract carcinoma. Ann Oncol, 16, 279.   DOI   ScienceOn
42 Tsavaris N, Kosmas C, Gouveris P, et al (2004). Weekly gemcitabine for the treatment of biliary tract and gallbladder cancer. Invest New Drugs, 22, 193-8.   DOI   ScienceOn
43 Valencak J, Kornek G, Raderer M, et al (2000). Gemcitabine for the treatment of advanced biliary tract carcinomas: evaluation of two different dose regimens. Onkologie, 22, 498-501.
44 Valle J, Wasan H, Palmer DH, et al (2010). Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer. New Engl J Med, 362, 1273-81.   DOI   ScienceOn
45 Von der Maase H, Sengelov L, Roberts J, et al (2005). Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. J Clin Oncol, 23, 4602.   DOI   ScienceOn
46 Von Delius S, Lersch C, Schulte-Frohlinde E, et al (2005). Phase II trial of weekly 24-hour infusion of gemcitabine in patients with advanced gallbladder and biliary tract carcinoma. BMC Cancer, 5, 61.   DOI   ScienceOn
47 Wang LR, Zhang GB, Chen J, et al (2011). RRM1 gene expression in peripheral blood is predictive of shorter survival in Chinese patients with advanced non-small-cell lung cancer treated by gemcitabine and platinum. J Zhejiang Univ Sci B, 12, 174-9.   DOI   ScienceOn
48 Won HS, Lee MA, Chung ES, et al (2010). Comparison of thymidine phosphorylase expression and prognostic factors in gallbladder and bile duct cancer. BMC Cancer, 19, 564.